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Abstract
Background: Mutations in the PTEN induced putative kinase 1 (PINK1) are implicated in early-
onset Parkinson's disease. PINK1 is expressed abundantly in mitochondria rich tissues, such as
skeletal muscle, where it plays a critical role determining mitochondrial structural integrity in
Drosophila.
Results: Herein we characterize a novel splice variant of PINK1 (svPINK1) that is homologous to
the C-terminus regulatory domain of the protein kinase. Naturally occurring non-coding antisense
provides sophisticated mechanisms for diversifying genomes and we describe a human specific non-
coding antisense expressed at the PINK1 locus (naPINK1). We further demonstrate that PINK1
varies in vivo when human skeletal muscle mitochondrial content is enhanced, supporting the idea
that PINK1 has a physiological role in mitochondrion. The observation of concordant regulation of
svPINK1 and naPINK1 during in vivo mitochondrial biogenesis was confirmed using RNAi, where
selective targeting of naPINK1 results in loss of the PINK1 splice variant in neuronal cell lines.
Conclusion:  Our data presents the first direct observation that a mammalian non-coding
antisense molecule can positively influence the abundance of a cis-transcribed mRNA under
physiological abundance conditions. While our analysis implies a possible human specific and
dsRNA-mediated mechanism for stabilizing the expression of svPINK1, it also points to a broader
genomic strategy for regulating a human disease locus and increases the complexity through which
alterations in the regulation of the PINK1 locus could occur.
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Background
PTEN induced putative kinase 1 gene (PINK1) is a serine-
threonine kinase directly linked to a recessive form of
familial parkinsonism [1-4]. A mutation at the nucleotide
binding site within the kinase domain renders the protein
unable to protect neuroblastoma cells from apoptosis,
whereas over expression of the native peptide protects SH-
SY5Y cells [1,3]. Over expressed tagged PINK1 localizes to
the mitochondria [2,4], raising the possibility that PINK1
phosphorylates and regulates proteins involved in oxida-
tive phosphorylation or the mitochondrial translocator
pore [5,6], processes linked to neuronal cell death [7,8].
Indeed, PINK1 inhibits mitochondrial cytochrome c
release, attenuating the general apoptosis machinery
[3,6], while mitochondrial localization is supported by
the existence of an 8.5 kDa mitochondrial import tag [2]
and  in vitro mitochondrial translocation [2]. Most
recently, Gandhi et al. [9] produced evidence that endog-
enous PINK1 protein locates to the mitochondrial mem-
branes, while three additional articles highlighted a
critical role for PINK1 in Drosophila flight muscle mito-
chondria [10-12]. A fourth study in Drosophila show an
antioxidant rescue of neurodegeneration induced by
knockdown of Pink1 [13]. It is clear, therefore, that PINK1
may play a rather central physiological role in neuronal
and myocyte energy metabolism, consistent with its abun-
dant expression in mitochondria-rich tissue [14] and con-
sistent with the proposed mitochondrial basis for
Parkinsonism.
The C-terminal end of the protein regulates PINK1 kinase
activity [2]. Intriguingly, a predicted novel short splice var-
iant of PINK1 would translate into a protein sequence
which represents the C-terminus portion of the protein.
Furthermore, a cis-transcribed non-coding natural anti-
sense (ncNAT) originating from the PINK1 gene locus is
predicted from the human EST databases [15] and is now,
very recently, listed in a natural antisense transcript data-
base [16]. According to the available well annotated data-
bases, PINK1 ncNAT is not apparent in other species. The
ncNAT demonstrates near complete sequence overlap
with the short PINK1 splice variant and only partial over-
lap with PINK1, at the 3'end. Widespread expression of
natural antisense transcripts (NAT) has, in recent times
[17-19], emerged as a potential mechanism for bringing
diversity and regulatory complexity to a surprisingly finite
human 'protein coding' genome [12]. While there are a
handful of examples of NAT (coding or non-coding)
which negatively regulate protein coding mRNA expres-
sion [20], few are associated with human disease [19] and
none have been shown to directly regulate a cis-tran-
scribed partner in a positive or concordant manner. In
addition, despite the annotation of several thousands of
ncNAT's in mammalian genomes, few have had their role
in mammalian biology clarified [17,20].
Greater appreciation of the mechanisms responsible for
regulating the PINK1 gene locus, beyond rare mutations,
is of importance for a number of reasons. For example, it
is likely that alteration of PINK1 function, regardless of
mechanism, would influence mitochondrial function
[1,10-12,21]. In addition, as PINK1 appears to influence
mitochondrial membrane potential [1] and mitochon-
drial dysfunction is implicated in many age related dis-
eases [22], studying the regulation of the PINK1  locus
during dynamic in vivo modulation of mitochondrial
function is likely to be relevant to human ageing. While it
is impossible to study this process in the adult human
brain, it is plausible to model gains in mitochondrial
function in adult human skeletal muscle [23] and exam-
ine the regulation of transcription from the PINK1 locus.
In doing so we reveal direct evidence that there is a dis-
cordant transcriptional response between the two coding
PINK1 splice variants, in vivo, during dynamic alterations
in mitochondrial function, whereas there is a concordant
regulation of short transcript variant of PINK1 (svPINK1)
by a cis-transcribed ncNAT (naPINK1) originating from
the PINK1 gene locus. Not only do we provide the first
direct evidence that a ncNAT can positively regulate the
abundance of a sense coding transcript in humans under
physiological conditions, we also highlight that the com-
plexity of PINK1 locus regulation is potentially greater in
humans than other species.
Results
Analysis of the PINK1 locus
Inspection of the PINK1 locus (Fig. 1A) revealed a poten-
tial for multiple PINK1 mRNA species. In addition to the
protein-coding PINK1 transcript, 2.6 kb long, the PINK1
locus encodes a shorter transcript, svPINK1, which almost
completely overlaps with the 5'end of a cis-transcribed
natural antisense transcript, naPINK1 and also overlaps
with the 3' portion of the full length PINK1 transcript.
svPINK1 is 1.6 kb long and has a unique 52 bp within its
first exon derived from the neighboring intronic region
[24]. This PINK1 splice variant represents the C-terminus
portion of the PINK1 protein. A model of the PINK1 pro-
tein structure was designed using homology modeling
(see Additional file 1) [25] where the region colored in
grey represents a predicted protein encoded by svPINK1
([26], Q9BXM7-2) which retains a phospho-threonine
binding domain and a significant portion of the protein
kinase domain (see Additional file 1). The 4.4 kb
naPINK1 transcript (Fig. 1A and 1B) is annotated as orig-
inating from the 'intergenic' region downstream of the 3'
end of the protein coding gene DDOST (which resides on
the opposite strand from PINK1). The predicted 5' end of
naPINK1 overlaps with the 3'UTR of DDOST and this
region contains no obvious promoter for naPINK1. As the
naPINK1 transcript appears to be an extension of the
DDOST transcript, this raises the possibility that the pro-BMC Genomics 2007, 8:74 http://www.biomedcentral.com/1471-2164/8/74
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moter for naPINK1 either resides within DDOST or it is
regulated by DDOST promoter. Interestingly, there was no
evidence, across seven species, for conservation of
naPINK1, even in the well characterized mouse genome
[15,27] or within a recently released natural antisense
transcript database [28].
An alignment of the 5' upstream regions (promoter) of
PINK1 in mouse and human indicate a high degree of
conservation, implying that PINK1 transcriptional regula-
tion may be similar across these species. A search for tran-
scription factor binding sites within the PINK1 5' region
[29] identified PPARγ and numerous myogenic transcrip-
tion factor binding sites (see Additional file 2), supporting
the robust expression of PINK1 in mitochondria rich stri-
ated muscle and the recently demonstrated and devastat-
ing impact of loss of PINK1 expression in Drosophila flight
muscle [21]. We also examined the genomic sequences of
DDOST and PINK1 (see Additional file 2). The intergenic
region and the last exons of both PINK1 and DDOST are
noticeably less conserved between human and mouse
than the rest of the locus (approximately 60% conserva-
tion compared with >80%), which supports the idea that
the region from where the naPINK1 originates, is specific
to the human genome. Interestingly, DDOST encodes the
AGE-R1 scavenger receptor, a counter regulatory mecha-
nism for advanced glycation end-product induced oxida-
tive stress [30], with a role in diabetes and ageing,
processes clearly relevant to Parkinson's disease [8]. Evi-
dence that this 'intergenic' region between the 3' end of
DDOST and the 5' end of naPINK1 is subject to post-tran-
scriptional regulation comes from the observation that
between the 3' end of DDOST and the 5' end of naPINK1,
there are numerous consensus sequences for endogenous
microRNA's (see Additional file 2) providing a potential
mechanism through which the naPINK1 transcript could
be processed from a large combined transcript (see
below).
Detection of the RNA transcripts from the PINK1 locus
We profiled, using Northern blot, a range of neuroblast-
oma cell lines to look for divergent expression of the
PINK1 related transcripts (with a view towards future cell
studies). Although no major differences between the cell
lines were detected, we confirmed expression of PINK1,
and produced the first direct evidence for the existence of
naPINK1 (Fig. 1B). svPINK1 was clearly of low abundance
(consistent with the estimated 20 fold lower abundance
using quantitative real-time PCR (qRT-PCR) specific
primer/probe based detection (Table 1). This transcript
was poorly visible by Northern blot of total RNA, but
became clearly detectable when using mRNA as the start-
ing material (Fig. 1B). To confirm the existence of the pre-
dicted svPINK1 transcript, we used 5' RLM RACE and then
cloned and sequenced the product, along with a pur-
chased cDNA clone (AK075225), representing the
svPINK1 genomic location. This strategy enabled rapid
verification that we had the correct size of product on an
agarose gel (Fig. 1C), before proceeding with sequencing.
In addition we used both random hexamer and Oligo
d(T)16 priming strategies to detect PINK1, svPINK1 and
naPINK1 expression in neuroblastoma cell lines using
qRT-PCR (see below). Detection of identical abundances
of svPINK1 and naPINK1 with both primer strategies indi-
cated that both svPINK1 and naPINK1 are polyadenylated
(data not shown). All primers and probes used in this
study can be found in Table 1 and there relative location
is illustrated in Fig. 1A.
In vivo human transcript regulation of the PINK1 genomic 
locus
If PINK1 plays a physiological role in human mitochon-
dria then its expression must be regulated in a manner
that is consistent with dynamic changes in mitochondrial
function. Convincingly, we demonstrate dynamic up-reg-
ulation of PINK1 expression during gain of mitochondrial
function (Fig. 2A–B). There was also a modest but signifi-
cant correlation (r = 0.34, p = 0.018) between the mito-
chondrial DNA (mtDNA) encoded complex I gene,
MTND4 expression and PINK1 mRNA. In vivo, svPINK1
demonstrated a diametrically opposed expression pattern
to PINK1 (Fig. 2A). This suggests that splicing is somehow
influenced by a requirement for PINK1 within the mito-
chondria. Strikingly, we observed in vivo an extremely
robust positive co-expression of svPINK1 mRNA and
naPINK1 (Fig. 2C). Thus, the change in svPINK1 expres-
sion was proportional to the change in naPINK1 expression
in vivo. Moreover, there was also a strong positive covari-
ance within individual human subjects for the changes in
svPINK1 and naPINK1 mRNA expression (Fig. 2D) pro-
viding an additional and highly convincing indication
that naPINK1 may regulate svPINK1 abundance in vivo at
physiological levels. In stark contrast, PINK1 does not co-
vary with naPINK1 in vivo, while the ratio of PINK1 to
svPINK1 is associated with the NAT expression pattern
(see Additional file 3). Hence, only the sense coded
mRNA that demonstrates near fully complementary over-
lap with the NAT appears co-expressed in vivo. Thus we
speculate that PINK1 may play a physiological role in reg-
ulating mitochondrial oxidative phosphorylation (con-
sistent with articles published during the review of our
manuscript, [10-12]), while svPINK1, which is homolo-
gous to the C-terminus end of the full-length protein, may
regulate PINK1 kinase function [2].
RNAi demonstrates that naPINK1 regulates svPINK1 
abundance
To explore the natural antisense relationship further, we
used short interfering RNA (siRNA) directed specifically
towards naPINK1 or PINK1 (Table 1 and Fig. 1A). Target-BMC Genomics 2007, 8:74 http://www.biomedcentral.com/1471-2164/8/74
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Mapping out the PINK1 locus (a) Figure 1
Mapping out the PINK1 locus (a). To validate the predicted transcripts from the PINK1 locus, Northern blotting and 5'-RLM 
RACE were performed (b-c). (a) A scaled overview of the PINK1 locus, presented along with the precise location of primer 
sites, siRNA target sites and Northern probe locations. The diagram represents the chromosomal coordinates for the PINK1 
gene annotated in the Ensembl gene browser (20,832,535–20,850,591, chromosome 1). Arrows indicate direction of transcrip-
tion (i.e PINK1 and svPINK1 are transcribed from left to right, while DDOST and naPINK1 are transcribed from right to left. (b) 
Total RNA was isolated from 4 neuroblastoma cell lines (SH-SY5Y (1), SK-N-SH (2), SK-N-AS (3), SK-N-F1 (4)) and poly ade-
nylated mRNA was isolated using an oligo d(T) magnetic bead kit (from a pool of total RNA from all cell lines) and analyzed by 
Northern blotting with a double stranded probe targeting PINK1 exon 8, and thus would detect naPINK1 (4.4 kb), PINK1 (2.6 
kb) and svPINK1 (1.6 kb). Three bands were detected of which two of them corresponded to the sizes of naPINK1 and PINK1, 
respectively. The third band is between 6 and 9 kb. It is plausible that it represents a larger transcript consisting of both the 
DDOST and the naPINK1 transcripts, which would result in a transcript of 6.4 kb. A fourth, band was detected in the mRNA 
preparation with a size that corresponds to svPINK1 (1.6 kb) consistent with the qRT-PCR abundance of svPINK1 (c) 5'-RLM 
RACE was performed to clone svPINK1 full-length cDNA. The svPINK1 RACE-product was confirmed using nested PCR. In 
parallel, as a size control, the same nested PCR was performed on a purchased clone (AK075225) containing the svPINK1 
sequence. This clone was found using BLAST at the NCBI database. The size of the PCR products were determined by agarose 
gel analysis, which demonstrated bands at ~854 bp for both templates, consistent with the predicted size of the svPINK1 
sequence, and the identify of both bands was then verified by sequencing.
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ing of the naPINK1 transcript in neuroblastoma cells had
no significant effect on the abundance of the PINK1 tran-
script (Fig. 3A–B). In stark contrast, svPINK1 was reduced
by 40% following selective knockdown of the cis-encoded
antisense transcript naPINK1 (Fig. 3C). Note that we used
siRNAs that targeted unique, non-overlapping, regions of
the 4.4 kb sequence of naPINK1 (siRNAs H and I, Table
1). These siRNA target an intronic sequence which can be
found in the unprocessed svPINK1 and PINK1 sequence
but which is within the mature naPINK1 mRNA sequence.
Although RNAi is supposed to follow an asymmetry rule
[31] it is possible that the guide siRNA could also direct
RNAi – against the intronic unprocessed PINK1 variant.
Not only do we think this is highly unlikely, but our data
directly demonstrate that this does not occur in the
present situation as such an action would result in knock-
down of both svPINK and PINK1, and this clearly does
not occur (compare Fig. 3B and Fig. 3D). When cDNA was
synthesized using oligo-d(T)16 primers, svPINK expres-
sion was reduced by ~60% following knockdown of the
naPINK transcript with AS siRNAs (Fig. 3D), consistent
with data generated using random hexamer priming (Fig.
3C). In addition, siRNA targeting a region on the first
exon of PINK1 (S PINK1-1) robustly knocked down
PINK1 mRNA but this did not significantly alter either
svPINK1 or naPINK1 expression (see Additional file 3).
Thus, it appears that when siRNA mediated cytosolic
knockdown of the polyadenylated naPINK1 transcript
occurs, svPINK1's abundance is reduced, which in turn
strongly supports the above concordant in vivo human
interactions between PINK1 mRNA and its ncNAT.
Discussions and conclusion
In the present study we demonstrate that a naturally
expressed non coding antisense RNA and a short splice
variant of PINK1 exist in human neuroblastoma cells and
human skeletal muscle tissue. We further demonstrate
that this NAT regulates the PINK1 locus in a manner that
involves stabilizing, or promotion of, the expression of
the PINK1 splice variant, svPINK1. This is the first com-
pelling evidence that an ncNAT positively modulates a
sense coding RNA at levels found in vivo in humans. Fur-
thermore, given that svPINK1 codes for a homologue of
the C-terminus of PINK1; a peptide sequence which regu-
lates PINK1 kinase activity [2], then modulation of
naPINK1 expression may have direct relevance in Parkin-
son's disease.
Teleologically, any process that regulates PINK1 activity
may influence Parkinson's disease progression and thus it
is important to consider the broader regulation of the
PINK1  locus. The scale of the FANTOM Consortium
mammalian antisense transcriptome project [17] enabled
robust estimations, using gene ontology based classifica-
tion scores, of the function of the coding genes which
have cis-transcribed associated NATs. For convergent NAT
species, the corresponding coding transcripts were most
likely translated into catalytic proteins involved in nucle-
otide metabolism, while for fully overlapping cis-tran-
scribed NAT species, many of the corresponding sense
mRNAs were translated into a protein with protein bind-
ing abilities or kinase activity. These statistical associa-
tions are clearly in agreement with the naPINK1 and
Table 1: 
Annotation Description Sequence 5'-3'
A PINK1 qRT-PCR forward primer GGACACGAGACGCTTGCA
PINK1 MGB probe TTTCGGCTGGAGGAGTA
PINK1 qRT-PCR reverse primer TTACCAATGGACTGCCCTATCA
B svPINK1 qRT-PCR forward primer GGGAGTCGTCGATGTGTGGTA
svPINK1 MGB probe AGGCCCTCTCCCCTC
svPINK1 qRT-PCR reverse primer GGCGCAGGGTACAGGGATA
C naPINK1 qRT-PCR forward primer AGCATGCATTGTTGAAATAGCCTTT
naPINK1 qRT-PCR reverse primer AGAGGAGACTACTTACCTGGTTCAAG
E Northern forward primer CCGCAAATGTGCTTCATCTA
Northern reverse primer GGCTAGTCAGGAGGGAAACC
F 5' RACE outer primer TCCCACTCCCGTAACTGAAC
5' RACE inner primer TCCTCAGTCCAGCCTCATCT
G RACE product internal forward primer ATTGGGAGTCGTCGATG
RACE product internal reverse primer CTCCATGCAGGGACATCA
H AS siRNA 1 sense strand GGAAGCUGUAGCUAGAACAUCUGUU
H AS siRNA 1 antisense strand AACAGAUCUUCUAGCUACAGCUUCC
I AS siRNA 2 sense strand CAGGUAAGUAGUCUCCUCUAUCAUU
I AS siRNA 2 antisense strand AAUGAUAGAGGAGACUACUUACCUG
J S-PINK1 siRNA (spanning two exons) sense strand GGAGAUCCAGGCAAUUUUUtt
J S-PINK1 siRNA (spanning two exons) antisense strand AAAAAUUGCCUGGAUCUCCtgBMC Genomics 2007, 8:74 http://www.biomedcentral.com/1471-2164/8/74
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Expression of PINK1, svPINK1 and naPINK1 in humans in vivo during gain in mitochondrial activity induced by 6 weeks of  endurance training (a-d) Figure 2
Expression of PINK1, svPINK1 and naPINK1 in humans in vivo during gain in mitochondrial activity induced by 6 weeks of 
endurance training (a-d). Total RNA was isolated from human muscle biopsies before and after activity to manipulate mito-
chondrial content. Expression of PINK1, svPINK1 and naPINK1 was achieved using quantitative real-time PCR (qRT-PCR). 
Mitochondrial Complex I activity demonstrates gain of mitochondrial content. Data are mean ± se and are presented as a per-
centage of the expression (or enzyme activity) before and after activity. (a) PINK1, svPINK1 and naPINK1 expression was 
determined after gain in mitochondrial activity (n = 24 for PINK1 and naPINK1, n = 23 for svPINK1 as the expression of 
svPINK1 in one paired sample was to low to measure). (b) Mitochondrial complex I activity and MTND4 mRNA were meas-
ured in muscle biopsies (n = 24) and the increase in enzyme activity is presented (c) Linear regression and correlation analysis 
of naPINK1 expression versus svPINK1 expression in human in vivo. Values compared were 18S rRNA adjusted CT-values from 
qRT-PCR analysis (n = 48). Dotted lines represent 95% confidence intervals. (d) Linear regression analysis of the changes in 
naPINK1 expression versus the changes in svPINK1 expression in the human in vivo model for mitochondrial biogenesis. Values 
compared were from the qRT-PCR analysis (18S adjusted CT-values before subtracted from 18S adjusted CT-values after 6 
weeks of endurance training, n = 24).
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Expression of naPINK1, PINK1 and svPINK1 following knockdown of naPINK1 with short interfering RNA (siRNA) (a-d) Figure 3
Expression of naPINK1, PINK1 and svPINK1 following knockdown of naPINK1 with short interfering RNA (siRNA) (a-d). 
Total RNA was isolated from neuroblastoma cell lines SK-N-MC and SH-SY5Y treated with two different siRNAs towards 
naPINK1 or an siRNA control which avoids targeting any known human sequence. Random hexamers were used in cDNA-syn-
thesis when not otherwise stated and gene expression was determined using qRT-PCR. Data are presented as mean ± SE of 
the percentage mRNA abundance related to control siRNA treated samples in each experiment. (a) naPINK1 expression fol-
lowing AS-siRNA knockdown (n = 12 for control siRNA and AS siRNA 1, n = 11 for AS siRNA 2, one sample was excluded 
due to failed transfection). (b) PINK1 expression following AS-siRNA knockdown (n = 12 for control siRNA and n = 23 for 
pooled results from the two siRNAs). (c) svPINK1 following AS-siRNA knockdown (n = 12 for control siRNA and AS siRNA 
1, n = 11 for AS siRNA 2). (d) To assess if naPINK1 and svPINK1 were polyadenylated and to exclude amplification of pre-
mRNA species, naPINK1 and svPINK1 expression was determined in a subset of samples (n = 6) from which an additional 
cDNA synthesis was performed, this time using oligo d(T)16. Absolute values obtained for gene expression were similar to the 
random hexamer protocol while the extent of the interaction between naPINK1 and svPINK1 was arguably clearer.
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PINK1/svPINK1 relationships. In the present study we
provide robust evidence of regulation by the naPINK1
transcript of the short variant of the Parkinson's disease
gene, PINK1, under conditions where the mRNA species
do not exceed their natural abundances (i.e. we do not
rely on artificial over expression to study these RNA inter-
actions).
A further point of interest is that the naPINK1 transcript is
formed at a region concurrent with the 3' end of the
DDOST gene. Examination reveals no obvious promoter
region within the overlapping region that encodes for
naPINK1 and the 3'UTR of DDOST, and so we can specu-
late that naPINK1 and DDOST  are transcribed from a
common promoter and that naPINK1 is a result of tran-
scription read-through. Our Northern blot analysis (Fig.
1B) supports this idea as we found a large transcript (6–7
kb) in both the total RNA and isolated mRNA prepara-
tions that could represent a DDOST-naPINK1 transcript
(which should be 6.4 kb). It has been postulated that neu-
rodegenerative diseases, such as Parkinson's, are associ-
ated with oxidative stress [7,8] and there is further
association between metabolic syndrome and neurode-
generation [32-34]. DDOST encodes a receptor that medi-
ates suppression of advanced glycation mediated cellular
oxidative stress and apoptosis [30]. While transcriptional
modulation of the DDOST gene has not been studied, it's
possible that metabolic syndrome induced transcriptional
modulation of DDOST  could subsequently result in
altered naPINK1 expression.
We must also ask how naPINK1 is able to 'stabilize' the
svPINK1 transcript. In general, the precise molecular
mechanisms through which ncNAT leads to the regula-
tion of a sense mRNA have not been clarified
[17,19,12,35]. RNA duplex formation leading to RNA
editing or degradation has been suggested, while anti-
sense induced chromosomal modifications has been
demonstrated and result in gene silencing. For example,
the murine ncNAT Air [36], which regulates the mater-
nally expressed igf2 receptor gene (igfr), highlights a
multi-gene interaction and provides a clear indication of
the complexity of NAT regulated transcription. Although
only over-lapping igf2r, the paternal antisense transcript
Air, silences the expression of igf2r, Slc22a2 and Slc22a3
through an ill-defined epigenetic modification [37]. There
are also examples where the antisense transcript regulates
transcription (N-myc), inhibits splicing (Rev-erbAα), trans-
port (mld) or promotes degradation (bFGF). These exam-
ples all involve a reduction in mRNA expression [35]. A
short co-transcribed ncNAT from the WT1 gene loci has
been associated with greater abundance of WT1 protein
[38] yet in vitro mechanistic studies failed to clarify this
effect. In our case, naPINK1 positively regulates the abun-
dance of svPINK1, both in vivo and during siRNA knock-
down experiments and thus we present a novel
observation for a ncNAT. Importantly, we demonstrate
that the detectable levels of naPINK1 and svPINK1 are
likely to be mature polyadenylated transcripts and so the
strong in vivo association may reflect a cytosolic interac-
tion. Insight into the mechanism through which naPINK1
may regulate svPINK1 also comes from the observation
that naPINK1 appears only to influence the abundance of
the near full length complementary cis  transcribed
svPINK1 sequence (only 52 bases of the 5' end of svPINK1
are non-complementary) suggesting a potential role for
dsRNA mediated stabilization. Recent data from chloro-
plasts, involving the mitochondrial ATP synthase gene
(atpB), demonstrated that a chloroplast mutant that pro-
duced a complementary coded atpb NAT mRNA resulted
in dsRNA formation, which prevented exonuclease medi-
ated degradation of the atpB mRNA [39]. It is also thought
that the degree of RNA editing, modulates activity of the
RNAi pathway, and it is plausible that this might explain
the current observations.
It was recently reported that siRNA mediated transcript
degradation can act in the nucleus of mammals [40], how-
ever this was demonstrated using a high concentration of
a siRNA containing a sequence known to result in off-tar-
get effects [41]. In our experiments, RNAi directed degra-
dation of naPINK1 is most likely to occur in the cytosol,
and we clearly demonstrate that this causes a significant
reduction of svPINK1. One could argue that naPINK1
may influence the splicing of PINK1 pre-mRNA. Under
this scenario, association between the 5' end of the PINK1
pre-processed mRNA with the natural antisense molecule
would somehow favor the alternative splicing process to
produce svPINK, starting from the intronic region
between Exon 4 and Exon 5 of PINK1, implying that
naPINK1 potentially masks a splicing inhibitor site. In
agreement with this idea, if one examines the in vivo rela-
tionship between the ratio of PINK1:svPINK1 RNA then
this is also linearly related to the expression level of the
naPINK1 (see Additional file 3). Nevertheless, this corre-
lation is driven by the svPINK1-naPINK1 relationship and
it is clear that PINK1 itself does not co-vary with the
naPINK1 RNA under the present experimental conditions
(see Additional file 3). Given that we demonstrate that
siRNA H and I do not target the pre-spliced version of
svPINK1 or PINK1 (which prior to nuclear processing and
export contain a common intronic region identical to the
siRNA targeted region on the naPINK1 transcript) and
that is possible that svPINK1-naPINK1 relationship
reflects alternative splicing, then we have to consider that
the synthetic siRNA may indeed direct RNAi within the
nucleus (naPINK1 knock-down) with a subsequent
change in PINK1 splicing, a consideration that merits
more robust investigation.BMC Genomics 2007, 8:74 http://www.biomedcentral.com/1471-2164/8/74
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The regulation of PINK1 protein expression is likely to be
complex, particularly under disease conditions [9-12,42].
Available evidence suggests that the full length protein is
processed (removal of its mitochondrial localization tag
[2,9]), resulting in the detection of at least two proteins on
a western blot. Neither of these proteins is consistent with
the predicted size of a svPINK1 protein (they are both too
large). Multiple shorter proteins have been found when
GST-tagged PINK1 is over-expressed and detected using
an antibody to GST [43] and while others have presented
western blots demonstrating a single protein band [44],
so far all commercial antibodies that we purchased repro-
ducibly (or received as a gift) give rise to >8 discrete bands
and thus are not reliable when profiling cell models. As
more reliable reagents become available [9] it will become
important to combine well designed RNAi experiments
with protein detection, to study the biochemical conse-
quence of loss of PINK1, svPINK1 and naPINK1 in
human cells. From a speciation perspective, there is prior
evidence that natural antisense RNA sequences can be
conserved selectively in higher mammals. A cis-tran-
scribed intronic antisense mRNA from the FAS receptor
gene, named Saf, alters FAS splice variant expression when
Saf is artificially over-expressed [45] and Saf appears only
to be conserved in primates. Future experiments will also
have to address the relative importance of naPINK and
svPINK in relation to PINK1 function. For example, the
relative abundance of naPINK approaches that of PINK1
in tumor cell lines, while naPINK1 is less abundant,
although clearly present in human muscle tissue. Ongo-
ing svPINK1 over-expression studies should resolve the
function of svPINK1, while we must also decide whether
svPINK1 is a truly independent 'gene' transcribed from
within the PINK1 genomic loci. In addition, given the
complexity of defining what merits being called a 'gene' it
is reasonable to suggest that a NAT, with a proven biolog-
ical function, should also be considered a gene.
In summary, we produce in vivo human data and support-
ive RNAi data which demonstrates that a non-coding RNA
so far limited to human expression, appears to 'stabilize' a
sense coding RNA. While our data is the first evidence that
endogenous levels of a non-coding antisense RNA influ-
encing a sense coded mRNA in a concordant fashion, we
can not rule out the possibility that naPINK1 recruits
additional cytosolic proteins [20] to bind and stabilize
svPINK1 in a more complex scenario than direct comple-
mentary hybridization. Given the close genomic associa-
tion between DDOST and naPINK specifically in the
human genome, we speculate that these two disease
related genes may be co-regulated, and uniquely so in
humans.
Methods
Cell culture and transfection
All cell culture reagents were purchased from GIBCO Inv-
itrogen (Sweden) unless otherwise stated. Neuroblastoma
cell lines SK-N-MC, SK-N-DZ, SK-N-F1, SK-N-AS were
sub-cultured in Minimal Essential Media (MEM) + Earle's
supplemented with 10% Fetal Bovine serum (FBS), 2 mM
L-glutamine, 1 mM sodium pyruvate, 1 × non-essential
amino acids, 100 U/ml penicillin and 100 µg/ml strepto-
mycin. Neuroblastoma cell lines SH-SY5Y and SK-N-Be(2)
was sub-cultured in 50% MEM + Earle's, 50% F12 (HAM)
supplemented with 10% FBS, 2 mM L-glutamine, 1 mM
sodium pyruvate, 1 × non-essential amino acids, 100 U/
ml penicillin and 100 µg/ml streptomycin. Neuroblast-
oma cell line SK-N-SH was sub-cultured in RPMI 1640
supplemented with 10% FBS, 2 mM L-glutamine, 1 × non-
essential amino acids 100 U/ml penicillin and 100 µg/ml
streptomycin. Cell cultures were maintained at 37°C in
5% CO2.
Prior to transfection, cells were counted using a hemacy-
tometer and 50,000 SK-N-MC cells or 70,000 SH-SY5Y
cells were seeded per well, into 6-well plates, 48 hours or
24 hours before transfection, respectively. SK-N-MC
attach more slowly to the surface after splitting than SH-
SY5Y and are sensitive to transfection if confluence is less
than 75%. On the other hand, transfection efficiency of
SH-SY5Y was improved by reducing the seeding density.
Transfection was performed using 0.25% Lipofectamine
2000 (Invitrogen, Sweden) and 20 nM siRNA in 2.5 ml
serum-containing cell culture media (without antibiotics)
according to the manufacturer's protocol. Briefly, Lipo-
fectamine 2000 was pre-mixed with Optimem, incubated
for 5 minutes and then mixed with siRNA. Following 20
minutes of incubation, the Lipofectamine 2000 – siRNA
mix was applied to cells. Media was changed 4 hours later
and cells were harvested 48 hrs after transfection for RNA
isolation. The siRNAs (Table S1) targeting naPINK1 were
designed using an on-line design tool called BLOCK-iT™
RNAi Designer (Invitrogen) and chemically synthesized
by Invitrogen. The siRNA targeting PINK1 (Table S1) was
a pre-validated siRNA from Ambion (siRNA ID # 1199)
and thus designed and chemically synthesized by
Ambion. The control siRNA was pre-designed by Ambion
to not target any gene in the genome (Silencer®Negative
Control#1, Ambion)
RNA isolation and quantitative real-time PCR (qRT-PCR)
Human muscle tissue biopsies were homogenized in TRI-
zol (Invitrogen) using a motor-driven homogenizer (Pol-
ytron, Kinematica) and total RNA was isolated according
to the manufacturer's protocol. In brief, two paired sam-
ples (before and after activity) were processed in parallel
in 1 ml TRIzol at any given time. The sizes of the tissues
ranged between 10 and 40 mg. Total RNA was dissolvedBMC Genomics 2007, 8:74 http://www.biomedcentral.com/1471-2164/8/74
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in 30 µl RNase-free water and quantified using a Nano-
drop (NanoDrop Technologies). Typically, the yield was
8–10 µg of total RNA from 20 mg of tissue. For the cell
samples, total RNA was isolated and on-column DNase-
treated using RNeasy Mini Kit (Qiagen) and RNase-Free
DNase set (Qiagen) according to the manufacturer's pro-
tocol. Total RNA was eluted in 30 µl of RNase-free water
and concentration was measured using a spectrophotom-
eter (UltroSpec 3000, Pharmacia Biotech). The typical
yield of SH-SY5Y was 700 ng and of SK-N-MC 5 µg of total
RNA per well in a 6-well plate.
1 µg muscle total RNA or 200 ng neuroblastoma cell total
RNA, in reaction volumes of 40 µl was reverse transcribed
using RT-PCR kit (Applied Biosystems) according to the
manufacturer's protocol. Typically, random hexamers
were used for the first strand cDNA synthesis. The advan-
tage of using random hexamers is the possibility to use
18S rRNA as an endogenous control in the quantitative
real-time PCR (qRT-PCR) analysis. However, to ensure
that mRNA and not pre-mRNA was reverse transcribed, a
second cDNA synthesis was performed for a sub-set of
samples, using oligo d(T)16 primer. This was used in an
attempt to exclude RNA species lacking poly A tails from
being reverse transcribed and only measure processed
mature polyadenylated mRNA transcripts in the subse-
quent qRT-PCR reaction.
Detection of mRNA was performed using an ABI-PRISM®
7000 Sequence Detection system (Applied Biosystems,
Foster City, CA, USA). Primers and MGB probes (Table 1)
were designed using Primer Express software (Applied
Biosystems). Primers were synthesized by Invitrogen and
MGB probes by Applied Biosystems. A pre-optimized
primer and probe assay for 18S rRNA was used as an
endogenous control (Applied Biosystems). For cDNA syn-
thesized with oligo d(T)16, β-actin was used as endog-
enous control. Primers and probes were pre-mixed with
TaqMan Universal Master Mix (for probes) or
SYBR®GREEN PCR Master Mix (for primers only)
(Applied Biosystems) and applied to 96-well MicroAmp
Optical plates (Applied Biosystems). cDNA aliquots of 4
µl were added in triplicates. Muscle cDNA was diluted
1:50 for detection of PINK1, 1:10 for detection of svPINK1
and naPINK1 and 1:500 for detection of 18S rRNA. Cell
cDNA was diluted 1:2 for detection of all target genes and
β-actin and 1:200 for detection of 18S rRNA. Samples
were accessed for DNA contamination by including cDNA
controls prepared without reverse transcriptase. The
amplification of genomic DNA typically amounted to a
maximum of <1% of the target gene when using the TRI-
zol protocol and even less when using RNeasy columns
including DNase-treatment. Thermal cycling conditions
were: 2 min at 50°C, 10 min at 95°C and 40 cycles of 15
s at 95°C and 1 min at 65°C.
Two-fold dilutions series were performed for all target
genes and endogenous controls to determine the amplifi-
cation efficiency (see Additional file 4). The ∆∆Ct method
was used to calculate relative changes in mRNA abun-
dance. The threshold cycle (CT) for 18S was subtracted
from the CT for the target gene to adjust for variations in
the cDNA synthesis. For the in vivo samples, the pre-inter-
vention values reflect baseline gene expression levels and
were subtracted from the post mitochondrial biogenesis
sample (induced under clinical trial conditions using an
endurance training model [23] to calculate the increase or
decrease in mRNA abundance. For the siRNA experi-
ments, 18S rRNA or β-actin adjusted CT-values were
related to the adjusted CT-value of the control-siRNA
treated sample in each experiment, transformed from log-
arithmic to linear and then a mean from all experiments
was calculated. The results are presented as percentage
mRNA abundance of control siRNA treated samples
(mean ± SE).
Northern blot
Neuroblastoma cell lines SK-N-MC, SH-SY5Y, SK-N-DZ,
SK-N-F1, SK-N-AS, SK-N-Be(2)  and SK-N-SH were har-
vested from 10 cm culture dishes with 2 ml of TRIzol (Inv-
itrogen) and total RNA was isolated as described in the
manufacturer's protocol. A pool of totalRNA from all the
above cell lines was used for polyadenylated mRNA isola-
tion using an oligo d(T) magnetic bead kit for mRNA iso-
lation (Promega) Total RNA and mRNA was examined by
Northern blotting. 10 µg of total RNA were separated on
an agarose gel (1.2%) containing 20 mM MOPS (pH 7.0)
and 6.7% formaldehyde. Ethidium bromide was added to
the gel to examine the distribution of RNA and to deter-
mine the abundance of 18S rRNA abundance across the
samples. The gel was run for 5 to 6 hours at 80 V and the
RNA was then transferred by capillary blotting overnight
onto a Hybond-XL membrane (Amersham Biosciences).
The membrane was pre hybridized at 42°C for at least 3 h
in hybridization solution containing 5 × SSC (1 × SSC is
0.15 M NaCl/0.015 M sodium citrate), 5 × Denhardt's (1
× Denhardt's is 0.02% Ficoll 400/0.02% polyvinylpyrro-
lidone/0.02% BSA), 0.5% (w/v) SDS, 50 mM sodium
phosphate (pH 6.5), 50% formamide and 100 µg/ml
sheared herring sperm DNA. Hybridization of the mem-
brane was performed overnight at 42°C in a hybridization
solution with the addition of denatured probe,
[32P]dCTP-labelled cDNA, corresponding to PINK1
amplified by PCR (primers in table 1) and labeled using a
random priming kit (Amersham Biosciences). After
hybridization, the solution was removed and the mem-
brane was washed twice for 30 min at room temperature
in a solution of 2 × SSC and 0.2% (w/v) SDS and twice for
15 min at 50°C in a solution of 0.1 × SSC and 0.2% (w/
v) SDS. The membrane was sealed in a plastic envelope
and then exposed and scanned in a Fuji Film Phosphoim-BMC Genomics 2007, 8:74 http://www.biomedcentral.com/1471-2164/8/74
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ager. Specific mRNA signals were analyzed with the Image
Gauge V3.45 program (Fuji Film).
5'-RACE and cloning of svPINK1
RNA Ligase Mediated Rapid amplification of cDNA ends
(RLM-RACE kit, Ambion) was performed according to the
manufacturer's protocol in order to clone svPINK1 full-
length cDNA. Briefly, total RNA from SK-N-MC cells (iso-
lated with TRIzol in the same way as for Northern blot
according to above) was used as template for the reaction.
A 45 base RNA adaptor oligonucleotide was ligated to the
5' end of the de-capped RNA population. The RNA was
reverse transcribed using RT-PCR kit from Applied Biosys-
tems instead of the reverse transcription reagents included
in the kit, as the latter gave a very weak signal. Reverse
transcription PCR was performed in a PTC-225 Peltier
Thermal Cycler (MJ Research) at 25°C for 10 minutes,
48°C for 30 minutes and 95°C for 5 minutes. PCR was
performed with the inner primer towards the ligated
adaptor sequence (provided in RLM-RACE kit, Ambion)
and the outer gene-specific primer (Table 1) designed
downstream of the predicted stop codon for svPINK1. A
second PCR analysis was performed using the inner
primer towards the ligated adaptor sequence (provided in
RLM-RACE kit, Ambion) and the inner gene-specific
primer (table 1) designed downstream of the predicted
stop codon for svPINK1 (see Additional file 4). The
sequence was confirmed by a third PCR analysis using
internal primers towards the previously amplified PCR
product. The 5' internal primer targets and thus the prod-
uct include the start of the svPINK1 sequence, containing
the 52 bases unique to this splice variant. A clone
(AK075225) containing the svPINK1 sequence was iden-
tified by database searching, purchased from National
Institute of Technology and Evaluation (NITE) Depart-
ment of Biotechnology Biological Resource Center
(NBRC), Kazusa-kamatari, Kisarazu, Chiba, 292-0818,
Japan [46] and used as template with the internal primers
in parallel with the obtained PCR-product from the RACE
experiment. The PCR products were validated by agarose
gel analysis which demonstrated bands at ~854 bp for
both templates, accordingly to the size of the sequence.
The product obtained from 5' RACE as well as the product
obtained from the AK075225 clone was cloned using
standard techniques and sequence analysis confirmed the
identity of these sequences.
Human in vivo skeletal muscle mitochondrial experiments
The study was approved by the ethics committee of the
Karolinska Institute, Stockholm, Sweden, and informed
consent was obtained from each of the volunteers. For
stimulating increases in mitochondrial function twenty-
four subjects trained under full clinical trial conditions on
a cycle ergometer as described previously [23]. Physiolog-
ical determination of increased aerobic capacity and the
muscle biopsy procedure were performed as described
[23,47]. All muscle biopsy samples were divided into sev-
eral portions and stored under liquid nitrogen until anal-
ysis. RNA analysis was as described above. Mitochondrial
enzyme activity was analyzed in whole muscle as
described previously. Briefly, muscle biopsies were
homogenized with a Potter-Elvehjem glass homogenizer
in a KCl buffer (100 mM KCl, 1 mM EDTA, 50 mM Tris, 5
mM MgCl2, 1.8 mM ATP, pH 7.2) to obtain a 5% homoge-
nate [48]. For Complex I measurements, 20 µl of whole
muscle homogenate was treated with 590 µl disruption
solution 1 (5 mM KH2PO4, 5 mM MgCl2, 0.5 g × l-1 essen-
tially fatty acid free bovine serum albumin) and then in
50 µl disruption buffer 2 (7.15 g × l-1 saponin dissolved in
disruption buffer 1). Seventy-two µl of the pretreated
homogenate was incubated with 75 µl of reagent (50 mM
KH2PO4, 5 mM MgCl2, 5 gl-1 BSA, 0.2 mM potassium cya-
nide, 4.8 µg × ml-1 Antimycine A (Sigma) and 0.12 mM
cytochrome c, pH7.5) for 7 min at 35°C. After the incuba-
tion, NADH was added to a final concentration of 0.15
mM, and the decrease in absorbance was monitored at
340 nm, for 1 min before and after the addition of roten-
one, 2 mg × l-1. The rotenone sensitive activity was calcu-
lated. The CV for this method is 8.9%.
Statistical analysis and bioinformatics
All data are presented as mean ± se unless otherwise
stated. ANOVA was utilized to analyze the human gene
expression responses. When a significant F ratio was
achieved, post hoc analysis was utilized to make individ-
ual comparisons. For cell based responses, unpaired t-tests
were utilized. Sample size and significance level is shown
for each graph. The genomic region including the PINK1
and DDOST genes was obtained from Ensembl v38 for
both human (Chromosome 1: 20825000 – 20865000
bp) and mouse (Chromosome 4: 137680000 –
137710000 bp). The human sequence was aligned to the
reverse complement of the mouse sequence using Kalign
[49]. The alignment was analyzed for conservation using
Kalignvu. Transcription factor binding sites were pre-
dicted using Consite [50] with a stringent cut-off criteria
of 15 bits, using all models in the Jaspar [30, 52] database.
A model of the PINK1 protein structure was created using
the structure of human protein kinase C theta type
(KPCT_HUMAN) in the region 377–625 which is homol-
ogous to PINK1 in the region 153–501 [25].
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